TF and neoplasm: Additionally, it is also pertinent to reiterate that an onco-TF-controlled CRISPRa (e.g., PSuv-CRISPRa adopted herein, see validations in Supplementary Fig. 1c) can provide an independent level of tumor selectivity in addition to that shaped by a PM2-ACRmax NOT gate (in an AND–NOT logic), to reduce the risk of possibly targeting normal cells.